An observational study in Myopia, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Recruiting at 1 site in France. Open to participants aged 4 Years to 8 Years. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Observational
Among 29 studies in Myopia with a site in France — 12 open to participants now, 13 under way, none of them phase 3. Myopia · France.
Among the 29 studies in Myopia with a site in France, this one is one of 8 that started in 2026, is one of 9 observational ones, reaches primary completion later than 11 of the 12 other live ones, and was the 23rd registered.
1,159 studies on the registry are indexed under Myopia; 225 are open to participants now.
Browse Myopia studies →12 of the 29 studies in Myopia with a site in France are open now. Recruiting first, the newest first:
Essilor International · Sites in France
Ages 12–17 · Healthy volunteers
Essilor International · Sites in France
Ages 6–14
Essilor International · Sites in France
Ages 6–12 · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 6–16
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.
This study: 4 Years to 8 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 3
First in 2009; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 150 across 204 observational studies indexed under Myopia.
Median enrollment 100 across the 20 interventional studies, 64 across the 9 observational. Of the 16 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 29 have an industry lead sponsor. The 10 most frequent:
Fondation Ophtalmologique Adolphe de Rothschild is the lead sponsor of 316 studies on the registry; 78 are open to participants now.
Fondation Ophtalmologique Adolphe de Rothschild has 6 studies filed under Myopia — fewer than ten, so there is no comparison to draw.
5 of the studies in Myopia with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340931Nantes University HospitalPilot Study on the Adaptation and Tolerance of Essilor® Myopia-control Spectacle Lenses | 2027-01-20 |
| NCT07440134Essilor InternationalVisual and Postural Behavior in Myopic and Non-Myopic Teenagers | 2027-05 |
| NCT06263946Essilor InternationalEssilor® Stellest® Lenses Multicentre European Study (SLOMES) | 2027-05-04 |
| NCT07297810Essilor InternationalDevelopment of a New Device and Method to Assess the Degree of Myopia and/or Astigmatism in Myopic People | 2027-06 |
| NCT07844408Essilor InternationalStudy of Eye Fatigue From Digital Screens and Its Impact on Visual Performance in People With Normal Vision and Myopia, With and Without Dry Eye Symptoms and Signs | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 29 studies in Myopia with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Myopia and high myopia are among the leading causes of visual impairment and blindness worldwide. The total number of people with myopia worldwide was estimated at 2.6 billion in 2020 and could reach 4.8 billion by 2050 unless preventive interventions are implemented.
Most epidemiological studies have focused on risk factors for myopia progression, with far fewer addressing the factors that cause a child to shift from emmetropia to myopia. The risk factors for the onset of myopia may be the same as those for myopia progression. However, for an equivalent level of risk exposure, it remains unclear why some children develop myopia while others do not.
Identifying the population most at risk of developing myopia would make it possible to propose preventive treatments aimed at delaying or preventing its onset. This would allow evaluation of the effectiveness of current myopia control treatments (peripheral defocus lenses, atropine, contact lenses) in preventing the onset of myopia, as well as future targeted treatments, including the potential benefit of early optical correction-a strategy once used but later abandoned due to a lack of robust scientific evidence.
The establishment of longitudinal follow-up of young emmetropic children at the French Institute of Myopia will enable the acquisition of high-quality imaging, allowing investigation of the association between advanced imaging parameters and external environmental factors with the onset of myopia.
Children aged 4 to 8 years at inclusion, emmetropic (cycloplegic refractive error between 0 and +2 diopters - inclusive - in spherical equivalent in each eye).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: annual follow-up
annual follow-up including ophtalmologic examination and biometry and behavioural questionnaires
To describe the incidence of myopia over the 2 years following inclusion in emmetropic children.
Onset of myopia within the 2 years following inclusion, defined as a spherical equivalent (SE) ≤ -0.50 D in at least one eye. Measurement of the spherical equivalent will be performed under cycloplegia using an autorefractor.
Time frame: Annual follow up : Year 1 and year 2
To describe the incidence of myopia over the 5 years following inclusion in emmetropic children.
Onset of myopia within the 5 years following inclusion, defined as a spherical equivalent (SE) ≤ -0.50 D in at least one eye. Measurement of the spherical equivalent will be performed under cycloplegia using an autorefractor.
Time frame: annual follow-up until Year 5
Started Feb 2026 (actual). Primary completion is estimated for Feb 2031, 60 months after the start.
Of 87 non-industry observational studies under Myopia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 90. This study's planned 60 months is above that.
Counting every sponsor, half of 96 studies reached it within 24 months; a quarter within 10 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondation Ophtalmologique Adolphe de Rothschild →